Description

Boston Scientific Just Lost Billions Over One Tiny Number—Here’s What Really Happened!

Boston Scientific entered this episode with the profile of a company that, on paper, still looked operationally strong. In its latest quarterly update, management pointed to more than $20 billion in annual sales, mid-teens organic growth in 2025, double-digit adjusted EPS growth, and continued momentum in two of its most important franchises: electrophysiology and WATCHMAN. Yet the stock fell sharply after investors zeroed in on one part of the CHAMPION trial data for WATCHMAN FLX: a 3.2% ischemic stroke rate in the device arm versus 2.0% for blood thinners. That figure quickly became the focal point of the entire debate, even though the broader dataset showed non-inferiority to oral anticoagulants on the composite efficacy endpoint and superiority on bleeding, which was one of the study’s core design goals.